We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.52%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.69B
AUM Growth
-$46.5M
Cap. Flow
-$20.4M
Cap. Flow %
-1.21%
Top 10 Hldgs %
61.89%
Holding
89
New
22
Increased
14
Reduced
20
Closed
19

Top Buys

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$31.1M
2
BPMC
Blueprint Medicines
BPMC
+$16.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$16.3M
4
ZTS icon
Zoetis
ZTS
+$15.3M
5
ZYME icon
Zymeworks
ZYME
+$13.7M

Top Sells

Rank Stock Value
1
XLRN
Acceleron Pharma
XLRN
+$25.4M
2
BIIB icon
Biogen
BIIB
+$25.4M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$19.8M
4
PODD icon
Insulet
PODD
+$19.2M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 91.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$37.5B
$346M 20.48%
3,102,960
+2,400
+0.1% +$275K
KRTX
2
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$239M 14.15%
1,953,077
+636
+0% +$73.4K
ASND icon
3
Ascendis Pharma A/S
ASND
$16.7B
$79.7M 4.72%
499,824
-22,099
-4% -$3.02M
JBIO
4
Jade Biosciences
JBIO
$1.22B
$78.9M 4.67%
107,391
– –
AZN icon
5
AstraZeneca
AZN
$263B
$67.8M 4.01%
564,136
+84,320
+18% +$9.82M
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$62.6M 3.71%
2,194,278
– –
VERA icon
7
Vera Therapeutics
VERA
$2.54B
$50.6M 2.99%
2,914,776
– –
MRK icon
8
CALL
Merck
MRK
$324B
$45.1M 2.67%
+600,000
New +$45.6M
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$41M 2.43%
222,094
+6,009
+3% +$1.18M
BOLT icon
10
Bolt Biotherapeutics
BOLT
$7.36M
$34.8M 2.06%
137,722
– –
ALGN icon
11
Align Technology
ALGN
$12B
$31.3M 1.85%
47,000
-93
-0.2% -$63.2K
ABBV icon
12
AbbVie
ABBV
$458B
$29.4M 1.74%
+272,600
New +$31.1M
GRTX
13
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$25M 1.48%
3,083,712
– –
HRTX icon
14
Heron Therapeutics
HRTX
$86.3M
$24.6M 1.46%
2,301,179
+833,504
+57% +$10.1M
BMY icon
15
CALL
Bristol-Myers Squibb
BMY
$127B
$23.7M 1.4%
+400,000
New +$26.3M
INZY
16
DELISTED
Inozyme Pharma
INZY
$23.5M 1.39%
2,028,308
– –
DXCM icon
17
DexCom
DXCM
$27.6B
$20.4M 1.21%
149,064
+14,212
+11% +$1.79M
BPMC
18
DELISTED
Blueprint Medicines
BPMC
$18.7M 1.11%
+181,860
New +$16.9M
REGN icon
19
PUT
Regeneron Pharmaceuticals
REGN
$68.8B
$18.2M 1.08%
+30,000
New +$18.6M
NXTC icon
20
NextCure
NXTC
$17.3M
$18M 1.07%
222,655
– –
AKUS
21
DELISTED
Akouos Inc
AKUS
$17.6M 1.04%
1,515,074
– –
UTHR icon
22
PUT
United Therapeutics
UTHR
$26.3B
$17.4M 1.03%
+94,500
New +$18.6M
HZNP
23
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$17.3M 1.02%
+157,487
New +$16.3M
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$15.8M 0.94%
157,488
+77,887
+98% +$9.13M
CYTK icon
25
Cytokinetics
CYTK
$11B
$15.2M 0.9%
426,632
-54,691
-11% -$1.61M
1
2 3 4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2021 Portfolio in Review

As of Q3 2021, Sofinnova Investments held 89 positions worth $1.69B, down 2.7% from $1.74B the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Sofinnova Investments's Q3 2021 filing shows 22 new, 14 increased, 20 reduced and 19 closed positions. Its largest new stake was AbbVie: 272,600 shares worth $29.4M. The largest sale was Acceleron Pharma, an estimated $25.4M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier.

  • Sofinnova Investments's largest Q3 2021 buy was AbbVie: 272,600 shares worth $29.4M.
  • Sofinnova Investments added most to Heron Therapeutics in Q3 2021, an estimated $10.1M increase.
  • Sofinnova Investments's biggest Q3 2021 reduction was Acceleron Pharma, cutting an estimated $25.4M.
  • Sofinnova Investments fully exited Neurocrine Biosciences in Q3 2021, selling an estimated $19.8M.
  • Sofinnova Investments's ten largest holdings make up 62% of its $1.69B portfolio in Q3 2021.
  • Sofinnova Investments opened 22 new positions and closed 19 in Q3 2021.
  • Sofinnova Investments's portfolio value fell 2.7% quarter-over-quarter to $1.69B.

Based on Sofinnova Investments's 13F filing for Q3 2021, filed 15 Nov 2021.